Response to dabrafenib after progression on vemurafenib in a patient with advanced BRAF V600E-mutant bronchial adenocarcinoma.

Publication

Response to dabrafenib after progression on vemurafenib in a patient with advanced BRAF V600E-mutant bronchial adenocarcinoma.

Journal Paper/Review - Nov 18, 2014

Schmid S, Siano Marco, Joerger M, Rodriguez Regulo, Müller J, Früh M

Citation

Schmid S, Siano M, Joerger M, Rodriguez R, Müller J, Früh M. Response to dabrafenib after progression on vemurafenib in a patient with advanced BRAF V600E-mutant bronchial adenocarcinoma. Lung Cancer 2014; 87:85-7.

Type

Journal Paper/Review (English)

Journal

Lung Cancer 2014; 87

Publication Date

Nov 18, 2014

Issn Electronic

1872-8332

Pages

85-7

Brief description/objective

We present the case of a patient with rapidly accelerated fibrosarcoma gene F (BRAF) mutated adenocarcinoma of the lung, responding to BRAF inhibitor dabrafenib after progressing on vemurafenib followed by docetaxel. The present case illustrates the potential benefit of successful rechallenge with a BRAF inhibitor, a well known phenomenon observed in other oncogenic driven molecular subtypes of non-small cell lung cancer (NSCLC) such as epidermal growth factor receptor mutation. Rechallenge with a BRAF inhibitor in BRAF mutated NSCLC should be considered, particularly in the absence of alternative therpateutic options.